KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.45
Today's Change
-0.01 (2.17%)
Day's Change
0.435 - 0.465
Trading Volume
8,955,000
Market Cap
649 Million
NOSH
1,441 Million
Latest Quarter
31-Mar-2024 [#1]
Announcement Date
27-May-2024
Next Quarter
30-Jun-2024
Est. Ann. Date
11-Aug-2024
Est. Ann. Due Date
29-Aug-2024
QoQ | YoY
178.38% | 868.50%
Revenue | NP to SH
3,488,986.000 | -54,453.000
RPS | P/RPS
242.08 Cent | 0.19
EPS | P/E | EY
-3.78 Cent | -11.91 | -8.40%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.19 | 0.00
QoQ | YoY
29.69% | 91.39%
NP Margin | ROE
-1.51% | 0.00%
F.Y. | Ann. Date
31-Mar-2024 | 27-May-2024
Latest Audited Result
31-Dec-2023
Announcement Date
29-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
29-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
3,404,481.000 | -77,452.000
RPS | P/RPS
236.22 Cent | 0.19
EPS | P/E | EY
-5.37 Cent | -8.37 | -11.94%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.20 | 0.00
YoY
87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Revenue | NP to SH
3,859,836.000 | 102,584.000
RPS | P/RPS
267.82 Cent | 0.17
EPS | P/E | EY
7.12 Cent | 6.32 | 15.82%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
232.45% | 868.5%
NP Margin | ROE
2.71% | 0.00%
F.Y. | Ann. Date
31-Mar-2024 | 27-May-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Total Positive Profit Years | 2 / 4 | 50.00% | 5 / 8 | 62.50% |
Continuous Quarters Of Positive Profit | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Continuous Quarters Of Profit Growth | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
Continuous Quarters Of Adjusted EPS Growth | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
Total Dividend Years | 0 / 4 | 0.00% | 2 / 8 | 25.00% |
Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Average ROE | 0.00% | 0.28% | ||
Average Net Profit Margin | -1.66% | -9.98% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Total Positive Profit Years | 2 / 5 | 40.00% | 7 / 10 | 70.00% |
Continuous Quarters Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Total Dividend Years | 4 / 5 | 80.00% | 9 / 10 | 90.00% |
Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Average ROE | 0.41% | 6.29% | ||
Average Net Profit Margin | -4.04% | -0.57% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 3,488,986 | 3,859,836 | 3,404,481 | 2,848,595 | 3,455,154 |
NP to SH | -54,453 | 102,584 | -77,452 | -31,457 | -126,869 |
Dividend | 0 | 0 | 0 | 48,015 | 39,519 |
Adjusted EPS | -3.78 | 7.12 | -5.37 | -2.18 | -8.80 |
Adjusted DPS | 0.00 | 0.00 | 0.00 | 3.33 | 2.74 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | 22.18% | 9.60% | 9.60% | 10.63% | 11.59% |
NP to Owner | 178.38% | 868.50% | 868.50% | 288.39% | 129.87% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | 178.40% | 868.80% | 868.80% | 288.48% | 129.88% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 2.48% | 0.98% | 22.48% | 13.38% | 11.71% | 35.50% | -3.02% | -1.47% | 19.51% |
NP to Owner | 29.69% | 57.08% | -73.10% | 232.45% | 180.86% | 426.11% | 87.25% | 38.95% | -146.21% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | 29.66% | 57.06% | -73.18% | 232.49% | 180.88% | 426.21% | 87.25% | 38.95% | -146.21% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Our government won't let this company go down one, likely outcome :
1. Pharma turn profitable for a few quarters, bursa then approved their regularization plan and get out of PN17
2. If they can't turn profitable, bursa rejects their regularization plan, then government will have no choice but to bailout pharma by privatizing it
2 months ago
RInvest, they will definitely keluar PN17, Malaysia won’t let Pharma GG. I want the price reach Pandemic level, but don’t don’t MCO la.
1 month ago
Price already up 30 % (9 cents) cents..prior to the QR announcement.. clearly information leaked very very early (3 days ahead) to those shark.
If SC/Bursa not siasat and no use la this gahment when dealing with glc company.
1 month ago
Newpayer01 - that's exactly what I'm banking on - keluar PN17 - will shoot up .... at least back to 42 cents
1 month ago
this is in fact a high potential stock with a very cheap price. If they change the way of managing (and i can see they are doing now) the company like rest of the pharma ind. Pharma price would be at least above rm3.
1 month ago
this is not a problematic company, its the gahmen yg forced them to hsndle covid vaccine till over supply..when kovid gone..stuck with oversupply dose.. ask Kj ler. now, gahmen hv silently help to fix the problem. Nx Qr will be more prolific..high probability Revenue over 1b. Current price consider low already..good to enter. Down side minimum..upper side. 50 cents 👍
2 weeks ago
Look at other pharma players, their shares are all above RM2. This is the reason I said Pharmaniaga is underrated and it should be priced about RM4 if they are managing it well like others.
1 week ago
current management good already, managed to submit their restructuring plan early this year, you compare with other PN17 company, take yearssss to submit even the first plan. % months olready, and Bursa should give the approval anytime soon. I would expect this month.. BTW, Next QR should touch 1 billion revenue. Imagine how many people in Indonesia?? They just open news branch in Feb 2024.. next QR will be full 3 months (mac - June) sales.
" In the Indonesia segment, the revenue growth was due to the surge in demand for products of existing principals and additional sales generated from the opening of two
new branches in February 2024."
1 week ago
it will keep moving up steadily until the next QR released, if the report is good it will goes up further above RM1, and how high it could goes higher depends on the consistency of their financial performance as well as dividend given.
1 week ago
Good morning guys, would like to congrats those who bought pharma at 30+- cents, the huge profit is awaiting us.
1 week ago
for those who still have bullets may consider to get a train ticket asap as the gap of the stock price as of now to it supposed to be is big. big potential stock for mid term good profit investment.
1 week ago
either regulation plan approved by Bursa or 1 billion revenue will makes this counter fly towards at least 50 cents! .
1 week ago
It will be keep going up for sure as the company is in good shape now and keep improving from varies aspects. Bear in mind pharma is essential and is must + Pharmaniaga is the sole appointed supplier of nation.
1 week ago
anticipating Bursa announcement about its regulation plan. Once out, should prepare how to act ..
6 days ago
patient.. next QR will produce revenue above 1 Billion.. and out from PN17 status!. Grab it while still below 50 cents.. end of year above 60 cents
4 days ago
And the catalyst that is likely to change the fortunes of the company — a proposed renounceable rights issue with warrants as a sweetener to shareholders that is slated to raise up to RM354.6 million; and, more importantly, a proposed private placement to a third-party investor or investors that could raise gross proceeds of up to RM300 million — could happen soon. Both the rights issue and placement are part of a regularisation plan to get Pharmaniaga out of PN17 classification, but are likely to have a far-reaching impact if management’s plans pan out.
1 day ago
got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅
8 hours ago
nuemeslau
too big to fail
2 months ago